All In Biotech

Drug Trial Radar · NCT05923099

A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-site, Parallel-group, Dose-finding Trial to Evaluate the Efficacy and Safety of Different Doses of Subcutaneously Administered LEO 138559 in Adult Subjects With Moderate-to-severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Feb 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 262 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

262

Actual

Start

Sep 20, 2023

Primary completion

Dec 11, 2024

Study completion Apr 9, 2025

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Jun 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to test different doses of the trial medicine (LEO 138559) and see how well they work and how safe they are at treating moderate to severe atopic dermatitis in adults. There will be 4 different doses, that will also be compared to a placebo (a dummy medicine that doesn't contain the active ingredient of LEO 138559). Each participant will be randomly assigned to one of the 4 doses of LEO 138559 or placebo. In all arms, injections of placebo may be used to mask the different doses. The trial will last up to 36 weeks, including a screening/washout period (up to 4 weeks), a treatment period (16 weeks), and a follow up period (16 weeks). The participants will visit the clinic 17 times. For the first 4 weeks of the treatment period, participants will visit the clinic every week. For the next 12 weeks of the treatment period, participants will visit the clinic every 2 weeks. For the 16 week follow up period, participants will visit the clinic every 4 weeks. The treatments will be given to the participants by staff at the clinic. They are given as an injection just under the skin. At each visit the doctor will check the participants atopic dermatitis and if they have had any side effects. Participants will also complete an electronic diary every day about their atopic dermatitis and quality of life. LEO 138559 is also called "Temtokibart".

Conditions

  • Atopic Dermatitis

Interventions

  • LEO 138559Drug

    LEO 138559 given by injection just under the skin

  • PlaceboDrug

    Placebo given by injection just under the skin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Eczema Area and Severity Index (EASI) ScoreTime frame: From baseline to Week 16

Locations

73 sites in 11 countries. Site status is shown where the registry gives one.

  • LEO Investigational Site

    Fountain Valley, California

  • LEO Investigational Site

    Los Angeles, California

  • LEO Investigational Site

    San Francisco, California

  • LEO Investigational Site

    Hialeah, Florida

  • LEO investigational site

    Indianapolis, Indiana

  • LEO investigational Site

    New Albany, Indiana

  • LEO Investigational Site

    Ann Arbor, Michigan

  • LEO Investigational Site

    New York, New York

  • LEO Investigational Site

    Raleigh, North Carolina

  • LEO Investigational Site

    Cincinnati, Ohio

  • LEO Investigational Site

    Mayfield Heights, Ohio

  • LEO Investigational Site

    North Charleston, South Carolina

  • LEO Investigational Site

    Edmonton, Albana, Canada

  • LEO Investigational Site

    Calgary, Alberta, Canada

  • LEO Investigational Site

    Calgary, Alberta, Canada

  • LEO Investigational Site

    Edmonton, Alberta, Canada

  • LEO Investigational Site

    Surrey, British Columbia, Canada

  • LEO Investigational Site

    Mississauga, Ontario, Canada

  • LEO Investigational Site

    Sherbrooke, Quebec, Canada

  • LEO Investigational Site

    Verdun, Quebec, Canada

  • LEO Investigational Site

    Náchod, Czechia

  • LEO Investigatonal Site

    Ostrava-Poruba, Czechia

  • LEO Investigational Site

    Prague, Czechia

  • LEO Investigational Site

    Prague, Czechia

  • LEO Investigational Site

    Dijon, France

  • LEO Investigational Site

    Nice, France

  • LEO Investigational Site

    Paris, France

  • LEO Investigational Site

    Rouen, France

  • LEO Investigational Site

    Martigues, Bouches-du-Rhône, France

  • LEO Investigational Site

    Augsburg, Germany

  • LEO Investigational Site

    Bad Bentheim, Germany

  • LEO Investigational Site

    Berlin, Germany

  • LEO Investigational Site

    Dresden, Germany

  • LEO Investigational Site

    Frankfurt am Main, Germany

  • LEO Investigational Site

    Freiburg im Breisgau, Germany

  • LEO Investigational Site

    Gera, Germany

  • LEO Investigational Site

    Kiel, Germany

  • LEO Investigational Site

    Leipzig, Germany

  • LEO Investigational Site

    Mahlow, Germany

  • LEO Investigational Site

    Münster, Germany

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.